Radiation Treatment with New Drugs for Metastatic Breast Cancer

Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer

Recruiting Observational Study
Breast Cancer Radiotherapy; Complications
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
300 (estimated)
Sponsor
Fondazione Policlinico Universitario Campus Bio-Medico · Other
Who this trial is looking for

This trial is looking for patients with stage IV breast cancer who are receiving new drug treatments. Participants will undergo radiation therapy while continuing their treatment to see how well they tolerate it.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have stage IV breast cancer
  • I am receiving systemic treatment with new drugs
  • I am eligible for radiation treatment

You may not be able to join if

  • I have had previous radiation treatment on the same site
  • I have absolute contraindications to radiotherapy
  • I am receiving systemic treatment as part of a clinical trial

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients suffering from stage IV breast cancer * Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors) * Candidates for radiation treatment (both p…
Contacts

Edy Ippolito, Prof

06225418011

e.ippolito@unicampus.it

CONTACT